S&P Futures
4,266.50 -10.25 (-0.24%) Dow Futures
33,907.00 -56.00 (-0.16%) Nasdaq Futures
13,450.50 -42.75 (-0.32%) Russell 2000 Futures
1,987.30 -1.80 (-0.09%) Crude Oil
88.11 0.00 (0.00%) Gold
1,776.20 -0.50 (-0.03%)
Algernon Pharmaceuticals Inc. (AGNPF)
Chart Events
Performance Outlook
| Previous Close | 2.8100 |
| Open | 3.0600 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 2.9407 - 3.2000 |
| 52 Week Range | 2.3015 - 9.2900 |
| Volume | |
| Avg. Volume | 2,089 |
| Market Cap | 6.25M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2770 |
| Earnings Date | Apr 27, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AGNPF
Related Research
- ALGERNON PHARMACEUTICALS INCAnalyst Report: CVS Health CorporationFollowing its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.RatingFair ValueEconomic Moat6 days agoMorningstar
- GlobeNewswire
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and Chronic Cough, at the 9th American Cough Conference in June, 2023. The American Cough Conference is the world’
- GlobeNewswire
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce additional results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough. After further review of the topline data, Ifenprodil was shown to be much more effective at reducing cough in patients
- ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals
The Power Play by The Market Herald has announced the release of new interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals on their latest news.
